Clinical Trials Directory

Trials / Terminated

TerminatedNCT00145145

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Phase I/II Study of Immunization With the MAGE-3.A1 Peptide Mixed With the Immunological Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Status
Terminated
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
1 (actual)
Sponsor
Ludwig Institute for Cancer Research · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purposes of this study are to determine whether immunization with the MAGE-3.A1 peptide mixed with CpG 7909 results in a detectable immune response; to determine the safety of this vaccine and to document the tumor response to the vaccine.

Detailed description

Patients will be vaccinated every two weeks on six occasions. On each vaccination day, the MAGE-3.A1 peptide (300 µg) mixed with CpG 7909 (5 mg) will be administered twice intradermally (10% of the dose each) and twice subcutaneously (40% of the dose each) in the arms and thighs. Tumor staging will be performed before inclusion and at week 13. PBL collections will be performed before starting the treatment, and at weeks 3, 7 and 13. They will provide the T lymphocytes for the immunological analysis. Additional cycles of immunization will be proposed to patients without tumor progression requiring another treatment. A second cycle of 3 injections at 6-week intervals will be started at week 17 with the same vaccine, followed by a third cycle of 12 injections at 3-month intervals starting at month 11. At any time, progression of the disease necessitating any treatment not allowed during the study, will result in study withdrawal.

Conditions

Interventions

TypeNameDescription
BIOLOGICALMAGE-3.A1 peptide and CpG 7909

Timeline

Start date
2005-01-12
Primary completion
2005-04-07
Completion
2008-04-28
First posted
2005-09-05
Last updated
2022-10-07
Results posted
2021-07-21

Locations

2 sites across 1 country: Belgium

Source: ClinicalTrials.gov record NCT00145145. Inclusion in this directory is not an endorsement.